A low-dose win could derisk a regulatory pathway for BMS’ LPA1 antagonist in idiopathic pulmonary fibrosis after a recently reported patient death, but a miss at the higher dose leaves analysts awaiting full data.
Starting next year, GSK plans to demolish existing buildings and construct new facilities to support clinical and commercial supply. The investment will create more than 300 new jobs over the next five years, Pennsylvania state officials said.
Much of the repetitive work that ties up middle managers — data entry, bookkeeping, trial balances, and tax return preparation — is already being done offshore.
Ernst & Young global revenues increased 4.7% to $57 billion in fiscal year 2026, with each of EY’s service lines and geographic areas posting revenue increases.
Gusto deepened its presence in the practice management space with updates to Gusto Pro for accountants, plus an expanded partner program with funding for marketing and business development.
TRexBio and Retension Pharmaceuticals are set to debut Friday, bringing this year’s biotech IPO count to 29 as the sector’s rebound continues. City Therapeutics and Iambic Therapeutics hope to push that number even higher.